SpringWorks Therapeutics (SWTX) Scheduled to Post Earnings on Thursday

SpringWorks Therapeutics (NASDAQ:SWTX) is scheduled to post its quarterly earnings results before the market opens on Thursday, May 2nd. Analysts expect SpringWorks Therapeutics to post earnings of ($1.19) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($1.24) by ($0.20). The company had revenue of $5.45 million during the quarter, compared to analyst estimates of $1.26 million. During the same quarter in the previous year, the business earned ($1.19) earnings per share. On average, analysts expect SpringWorks Therapeutics to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

SpringWorks Therapeutics Stock Down 1.4 %

NASDAQ:SWTX opened at $43.38 on Thursday. The stock’s 50-day simple moving average is $47.83 and its 200 day simple moving average is $37.56. The firm has a market capitalization of $3.20 billion, a PE ratio of -8.44 and a beta of 0.83. SpringWorks Therapeutics has a twelve month low of $18.00 and a twelve month high of $53.92.

Wall Street Analysts Forecast Growth

SWTX has been the topic of several research analyst reports. Wedbush raised their price objective on SpringWorks Therapeutics from $60.00 to $70.00 and gave the company an “outperform” rating in a research note on Monday, February 26th. JPMorgan Chase & Co. raised their price objective on SpringWorks Therapeutics from $73.00 to $74.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. Barclays lifted their price target on SpringWorks Therapeutics from $47.00 to $63.00 and gave the company an “overweight” rating in a research note on Thursday, February 29th. HC Wainwright lifted their price target on SpringWorks Therapeutics from $73.00 to $74.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Finally, Guggenheim initiated coverage on SpringWorks Therapeutics in a research note on Monday, February 5th. They set a “buy” rating and a $75.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, SpringWorks Therapeutics has an average rating of “Buy” and an average price target of $68.00.

Insider Buying and Selling

In related news, insider Daniel Pichl sold 15,000 shares of SpringWorks Therapeutics stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $50.10, for a total value of $751,500.00. Following the transaction, the insider now directly owns 45,212 shares of the company’s stock, valued at $2,265,121.20. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 7.61% of the stock is owned by insiders.

About SpringWorks Therapeutics

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.